VVY — Vivoryon Therapeutics NV Balance Sheet
0.000.00%
Last trade - 00:00
- €11.76m
- -€30.44m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 3.78 | 41.5 | 26.3 | 17.7 | 30.3 |
Net Total Receivables | 0.091 | 0.6 | 0.129 | 0.293 | 0.256 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 3.98 | 45.4 | 28.8 | 20.2 | 30.7 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.056 | 0.465 | 0.39 | 0.285 | 0.176 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 4.05 | 45.9 | 29.8 | 24.5 | 31.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.964 | 0.93 | 1.32 | 5.05 | 3.27 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 2.82 | 3.2 | 3.53 | 7.96 | 4.87 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 1.23 | 42.7 | 26.2 | 16.6 | 26.5 |
Total Liabilities & Shareholders' Equity | 4.05 | 45.9 | 29.8 | 24.5 | 31.4 |
Total Common Shares Outstanding |